Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs MyFastRx

Aurelius Health Group
Graded #311

Lower grade

vs+6.799999999999997
MyFastRx
Graded #161

Higher grade

The verdict

MyFastRx takes it — 67.6/100 to 60.8/100.

MyFastRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMyFastRx +22
54
76
Dose & formulationMyFastRx +20
52
72
Clinical oversightAurelius Health Group +10
76
66
Labs & monitoringAurelius Health Group +11
63
52
FulfillmentMyFastRx +22
61
83
Contract termsAurelius Health Group +20
61
41
Aurelius Health Group · left barMyFastRx · right bar

The numbers

MetricAurelius Health GroupMyFastRx
WeighScore60.8/10067.6/100
GradeCC
Scorecard rank#311#161
SemaglutideNot disclosed$169/mo
Tirzepatide$199/mo (microdose tier, compounded)$249/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #311 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • The advertised $89 is a first-month new-patient rate; every month after it is $199
  • This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
  • No state count is published, only 'most US states', confirmed at intake
  • The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
  • Compounded tirzepatide is not an FDA-approved finished product
MyFastRx

Graded #161 · C

Strengths

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Where it loses points

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard